Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U. Farolfi A, et al. Among authors: casanova c. Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x. Sci Rep. 2020. PMID: 33097745 Free PMC article.
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U. Farolfi A, et al. Among authors: casanova c. Target Oncol. 2018 Aug;13(4):469-479. doi: 10.1007/s11523-018-0574-1. Target Oncol. 2018. PMID: 29948780
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S. Musacchio L, et al. Among authors: casanova c. Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22. Br J Cancer. 2022. PMID: 35869143 Free PMC article.
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R. Genestreti G, et al. Among authors: casanova c. Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24. Clin Lung Cancer. 2015. PMID: 25983005
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone).
Genestreti G, Ampollini L, Burgio MA, Rolli L, Sanna S, Scarpi E, Monti M, Burgio SL, Giannone L, Santo A, Mezzetti M, Casanova C, Buosi R, Rusca M, Amadori D, Gavelli G. Genestreti G, et al. Among authors: casanova c. Ann Surg Oncol. 2013 Sep;20(9):2958-63. doi: 10.1245/s10434-013-3018-2. Epub 2013 May 26. Ann Surg Oncol. 2013. PMID: 23709100
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Dazzi C, Cariello A, Casanova C, Verlicchi A, Montanari M, Papiani G, Freier E, Mazza V, Milandri C, Gamboni A, Papi M, Leoni M, Cruciani G, Vertogen B. Dazzi C, et al. Among authors: casanova c. Clin Lung Cancer. 2013 Jan;14(1):28-33. doi: 10.1016/j.cllc.2012.03.003. Epub 2012 Apr 25. Clin Lung Cancer. 2013. PMID: 22537509 Clinical Trial.
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, Chiari R, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P. Canale M, et al. Among authors: casanova c. Clin Cancer Res. 2017 May 1;23(9):2195-2202. doi: 10.1158/1078-0432.CCR-16-0966. Epub 2016 Oct 25. Clin Cancer Res. 2017. PMID: 27780855
420 results